One Kendall Square 1400W, Suite 14201
We are developing a fundamentally different treatment for repeat expansion disorders including Huntington's disease, myotonic dystrophy and spinocerebellar ataxias by addressing the underlying cause of the genetic dysfunction that drives disease onset and progression. To accomplish this goal, we've assembled a team with decades of expertise across drug discovery, genetics, clinical research and operations. We're supported by a top-tier syndicate of investors who share our commitment to transforming the lives of patients and families affected by repeat expansion disorders.
Home or Community